MediSapiens

Integrating the world’s genomics data

MediSapiens makes the world’s genomics data readily available. MediSapiens hosts the world’s largest unified gene expression database, which is used by biopharmaceutical companies in developing next generation personalized medicines, and by oncologists in choosing the optimal cancer treatments. As cancer is a highly personal and genetic disease, the MediSapiens data is able to express the oncogenic pathways in a patient’s tumor. By visualizing the genetic signature of the patient, they become optimally treatable. MediSapiens also provides a gene expression reference for biopharmaceutical research.

MediSapiens offers powerful easy-to-use visualization tools and advanced bioinformatics libraries designed to help biologists better understand genomics data.

MediSapiens believes that data matters and offers open access to the source data – the data being completely open for the development of SQL queries and R functions. Through the open access clients have been able to integrate their own data with that of MediSapiens’ and with high throughput screening (HTS) and next generation sequencing data.

Investors

VTT Ventures OyAloitusrahasto Vera OyEqvitec ETF III K/SLifeline Ventures AB,
Management

Additional Information

CEO Sami Kilpinen
+358 45 847 8878
contact(at)medisapiens.fi
medisapiens.com

  • Contact Us

    Antti Sinisalo
    CEO
    +358 40 5248751
  • Entrepreneur-in-Residence
  • VTT Ventures Ltd

    VTT Ventures Ltd.’s mission is to focus on extracting value from VTT technology in developing VTT based high-tech companies with international growth potential.